BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer. Rationale and design of the trial of the Southeast Co-operative Urological Group, The Netherlands.
van der Meijden
P M
PM
Department of Urology, University of Nijmegen, The Netherlands.
Debruyne
F M
FM
Steerenberg
P A
PA
de Jong
W H
WH
Doesburg
W
W
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage / Q000145:classification / Q000627:therapeutic use*; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000628:therapy; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000628:therapy; D003556:Cystitis / Q000139:chemically induced / Q000209:etiology; D006801:Humans; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage / Q000627:therapeutic use*; D015337:Multicenter Studies as Topic; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011897:Random Allocation; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000628:therapy*
D001500:BCG Vaccine; D008937:Mitomycins; D016685:Mitomycin